ASP4132
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma
Conditions
Lymphoma, Refractory Solid Tumors, Advanced Cancer
Trial Timeline
Mar 23, 2015 → Apr 27, 2018
NCT ID
NCT02383368About ASP4132
ASP4132 is a phase 1 stage product being developed by Astellas Pharma for Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02383368. Target conditions include Lymphoma, Refractory Solid Tumors, Advanced Cancer.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02383368 | Phase 1 | Completed |
Competing Products
20 competing products in Lymphoma